Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib

Experimental Hematology

Volumn 38, Issue 1, 2010, Pages 27-37

  Mor Tzuntz, Rahav ^a   Uziel, Orit ^a   Shpilberg, Ofer ^a   Lahav, Judith ^a   Raanani, Pia ^a   Bakhanashvili, Mary ^b   Rabizadeh, Esther ^a   Zimra, Yael ^a   Lahav, Meir ^a   Granot, Galit ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RNA; TELOMERASE;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG INDICATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; DNA PRIMERS; GENES, ABL; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 71549161721     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.10.005     Document Type: Article

References (51)

1. Melo J.V., and Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7 (2007) 441-453
2. Jabbour E., Cortes J.E., Giles F.J., O'Brien S., and Kantarjian H.M. Current and emerging treatment options in chronic myeloid leukemia. Cancer 109 (2007) 2171-2181
3. Hehlmann R., Hochhaus A., and Baccarani M. Chronic myeloid leukaemia. Lancet 370 (2007) 342-350
4. Gumireddy K., Baker S.J., Cosenza S.C., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 102 (2005) 1992-1997
5. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
6. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
7. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
8. Gambacorti-Passerini C., Barni R., le Coutre P., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92 (2000) 1641-1650
9. Thomas J., Wang L., Clark R.E., and Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
10. Illmer T., Schaich M., Platzbecker U., et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
11. Lankat-Buttgereit B., Hörsch D., Barth P., Arnold R., Blöcker S., and Göke R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 71 (2005) 131-140
12. Uziel O., Fenig E., Nordenberg J., et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 92 (2005) 1881-1891
13. Wihlidal P., Karlic H., Pfeilstöcker M., Klaushofer K., and Varga F. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res 32 (2008) 437-443
14. Shay J.W., and Keith W.N. Targeting telomerase for cancer therapeutics. Br J Cancer 98 (2008) 677-683
15. Kim S., Kaminker P., and Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 21 (2002) 503-511
16. Aisner D.L., Wright W.E., and Shay J.W. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 12 (2002) 80-85
17. Kang S.S., Kwon T., Kwon D.Y., and Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274 (1999) 13085-13090
18. Liu J.P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 13 (1999) 2091-2104
19. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
20. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33 (1997) 787-791
21. Tauchi T., Shin-ya K., Sashida G., et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25 (2006) 5719-5725
22. Chen S.M., Tao Z.Z., Hua Q.Q., et al. Inhibition of telomerase activity in cancer cells using short hairpin RNA expression vectors. Cancer Invest 25 (2007) 691-698
23. Zhou J.H., Zhang H.M., Chen Q., et al. Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma. World J Gastroenterol 9 (2003) 1808-1814
24. Glukhov A.I., Zimnik O.V., Gordeev S.A., and Severin S.E. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem Biophys Res Commun 248 (1998) 368-371
25. Villa R., Folini M., Porta C.D., et al. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis 24 (2003) 851-859
26. Drucker L., Uziel O., Tohami T., et al. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol 64 (2003) 415-420
27. Phatak P., and Burger A.M. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 152 (2007) 1003-1011
28. Campbell L.J., Fidler C., Eagleton H., et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 20 (2006) 671-679
29. Brummendorf T.H., Ersoz I., Hartmann U., et al. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. Ann N Y Acad Sci 996 (2003) 26-38
30. Tauchi T., Nakajima A., Sashida G., et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 8 (2002) 3341-3347
31. Hartmann U., Balabanov S., Ziegler P., et al. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol 33 (2005) 542-549
32. Bakhanashvili M., and Hizi A. Fidelity of the reverse transcriptase of human immunodeficiency virus type 2. FEBS Lett 306 (1992) 151-156
33. Zhu X., Kumar R., Mandal M., et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci U S A 93 (1996) 6091-6095
34. Dan S., Naito M., and Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ 5 (1998) 710-715
35. Opitz O.G. Telomeres, telomerase and malignant transformation. Curr Mol Med 5 (2005) 219-226
36. Yang Y., Chen Y., Zhang C., Huang H., and Weissman S.M. Nucleolar localization of HTERT protein is associated with telomerase function. Exp Cell Res 277 (2002) 201-209
37. Kharbanda S., Kumar V., Dhar S., et al. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol 10 (2000) 568-575
38. Bakalova R., Ohba H., Zhelev Z., Ishikawa M., Shinohara Y., and Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol 66 (2003) 1879-1884
39. Burchert A., Wang Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005) 1774-1782
40. Kharas M.G., and Fruman D.A. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65 (2005) 2047-2053
41. Krugmann S., Cooper M.A., Williams D.H., Hawkins P.T., and Stephens L.R. Mechanism of the regulation of type IB phosphoinositide 3OH-kinase byG-protein betagamma subunits. Biochem J 362 (2002) 725-731
42. Brock C., Schaefer M., Reusch H.P., et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol 160 (2003) 89-99
43. Torres J., Rodriguez J., Myers M.P., et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 278 (2003) 30652-30660
44. Jacquel A., Herrant M., Legros L., et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17 (2003) 2160-2162
45. Brümmendorf T.H., Holyoake T.L., Rufer N., et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95 (2000) 1883-1890
46. Zhang W., Piatyszek M.A., Kobayashi T., et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 2 (1996) 799-803
47. Counter C.M., Gupta J., Harley C.B., Leber B., and Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85 (1995) 2315-2320
48. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., and Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 60 (2000) 610-617
49. West K.A., Castillo S.S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5 (2002) 234-248
50. Kawauchi K., Ogasawara T., Yasuyama M., and Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 31 (2003) 11-17
51. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., and Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 108 (2006) 3504-1353